Morphine and QT Prolongation
Morphine is a low-risk opioid that does not cause clinically significant QT interval prolongation at routine therapeutic doses. 1, 2
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for morphine sulfate injection does not list QT prolongation as a warning, precaution, or adverse effect 1. The cardiovascular warnings focus on:
- Cardiovascular instability with high doses (from sympathetic hyperactivity and catecholamine release)
- Peripheral vasodilation causing orthostatic hypotension
- Histamine release effects
Notably absent from the extensive warnings section is any mention of QT prolongation or torsades de pointes (TdP), which would be prominently featured if this were a recognized risk.
Supporting Research Evidence
A comprehensive 2018 literature review specifically categorized opioids by their arrhythmogenic risk 2:
- High-risk opioids: Methadone (causes QT prolongation and TdP even at low doses)
- Intermediate-risk opioids: Tramadol and oxycodone (may cause QT prolongation at high doses)
- Low-risk opioids: Morphine and buprenorphine (do not produce QT prolongation or TdP at routine doses)
This classification is further supported by a 2009 controlled study that directly compared morphine to methadone 3. While methadone showed significant QTc prolongation (mean difference 41.7 ± 7.8 ms, p<0.0001), morphine showed no significant QTc prolongation (mean difference 9.0 ± 6.1 ms, p=0.15).
Clinical Context from Guidelines
The 2010 AHA/ACC scientific statement on TdP prevention identifies methadone and haloperidol as high-risk drugs but does not include morphine in discussions of QT-prolonging agents 4. The 2017 AHA update on hospital ECG monitoring specifically discusses methadone's QT prolongation risk but again omits morphine from this concern 5.
Clinical Implications
You do not need routine ECG monitoring for QT prolongation when prescribing morphine at standard analgesic doses. The cardiovascular monitoring priorities with morphine should focus on:
- Respiratory depression (the primary risk)
- Blood pressure and orthostatic changes
- Signs of histamine release (flushing, pruritus)
Common pitfall: Do not confuse morphine's cardiovascular safety profile with that of methadone. While both are opioids, methadone carries substantial QT prolongation risk requiring ECG monitoring, whereas morphine does not share this liability.